Cargando…

Therapeutic Landscape of Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

Human epidermal growth factor receptor 2–positive breast cancer (HER2+BC) is a common malignancy that is prone to recurrence and metastasis in the early stages, resulting in a poor prognosis for patients. Many studies have suggested that targeted therapy promotes clinical outcomes in HER2+BC. With t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xie, Jindong, Zou, Yutian, Gao, Ting, Xie, Liming, Tan, Duxun, Xie, Xiaoming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9067050/ https://www.ncbi.nlm.nih.gov/pubmed/35499382 http://dx.doi.org/10.1177/10732748221099230

Ejemplares similares

Landscape of cancer-associated fibroblasts identifies the secreted biglycan as a protumor and immunosuppressive factor in triple-negative breast cancer
por: Zheng, Shaoquan, et al.
Publicado: (2022)

Epidermal growth factor receptor in breast carcinoma: association between gene copy number and mutations
por: Lv, Ning, et al.
Publicado: (2011)

A Novel Platelet-Related Gene Signature for Predicting the Prognosis of Triple-Negative Breast Cancer
por: Xie, Jindong, et al.
Publicado: (2022)

Evolving landscape of human epidermal growth factor receptor 2-positive breast cancer treatment and the future of biosimilars
por: Jackisch, Christian, et al.
Publicado: (2017)

The Pan-Cancer Multi-Omics Landscape of FOXO Family Relevant to Clinical Outcome and Drug Resistance
por: Xie, Jindong, et al.
Publicado: (2022)

Establishment of a Cell Necroptosis Index to Predict Prognosis and Drug Sensitivity for Patients With Triple-Negative Breast Cancer
por: Xie, Jindong, et al.
Publicado: (2022)

Landscape of Epidermal Growth Factor Receptor Heterodimers in Brain Metastases
por: Lim, Malcolm, et al.
Publicado: (2022)

The Single‐Cell Landscape of Intratumoral Heterogeneity and The Immunosuppressive Microenvironment in Liver and Brain Metastases of Breast Cancer
por: Zou, Yutian, et al.
Publicado: (2022)

Is Acupuncture an Ideal Adjunctive Treatment for Cancer-Related Fatigue? Comment on Choi et al. Acupuncture for Managing Cancer-Related Fatigue in Breast Cancer Patients: A Systematic Review and Meta-Analysis. Cancers 2022, 14, 4419
por: Hu, Xiaoqian, et al.
Publicado: (2022)

CDK4/6 inhibitors for hormone receptor-positive/human epidermal growth factor receptor 2 negative advanced breast cancer: A rapid health technology assessment
por: Gu, Hangye, et al.
Publicado: (2023)

N6-methyladenosine regulated FGFR4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancer
por: Zou, Yutian, et al.
Publicado: (2022)

Epidermal Growth Factor Receptors and Breast Cancer
por: Farndon, J. R., et al.
Publicado: (1989)

CircEPSTI1 Promotes the Proliferation of HER2-Positive Breast Cancer Cells via circEPSTI1/miR-145/ERBB3 Axis
por: Zhang, Yue, et al.
Publicado: (2022)

Pyrotinib in combination with letrozole for hormone receptor-positive, human epidermal growth factor receptor 2-positive metastatic breast cancer (PLEHERM): a multicenter, single-arm, phase II trial
por: Hu, Zhe-Yu, et al.
Publicado: (2023)

Management of breast cancer brain metastases: Focus on human epidermal growth factor receptor 2-positive breast cancer
por: Yuan, Peng, et al.
Publicado: (2017)

Prognosis and Dissection of Immunosuppressive Microenvironment in Breast Cancer Based on Fatty Acid Metabolism-Related Signature
por: Tang, Yuhui, et al.
Publicado: (2022)

Integrative Analysis of KCNK Genes and Establishment of a Specific Prognostic Signature for Breast Cancer
por: Zou, Yutian, et al.
Publicado: (2022)

PIK3CA Mutations Drive Therapeutic Resistance in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
por: Rasti, Aryana R., et al.
Publicado: (2022)

Human epidermal growth factor receptor 2 positive rates in invasive lobular breast carcinoma: The Singapore experience
por: Kee, Ga-Jing, et al.
Publicado: (2020)

The epidermal growth factor receptor family in breast cancer
por: Koutras, Angelos K, et al.
Publicado: (2008)

Expression of T-Lymphocyte Markers in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
por: Lee, Changro, et al.
Publicado: (2016)

FTY720 in resistant human epidermal growth factor receptor 2-positive breast cancer
por: Chung, Wei-Pang, et al.
Publicado: (2022)

Tyrosine kinase inhibitors and human epidermal growth factor receptor-2 positive breast cancer
por: Abunada, Aya, et al.
Publicado: (2023)

Nuclear epidermal growth factor receptor as a therapeutic target
por: Atwell, Benjamin, et al.
Publicado: (2023)

Potentiating Therapeutic Effects of Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer
por: You, Kyu Sic, et al.
Publicado: (2021)

Novel Implication of the Basement Membrane for Breast Cancer Outcome and Immune Infiltration
por: Tian, Wenwen, et al.
Publicado: (2023)

Risk factors and survival outcomes in patients with breast cancer and lung metastasis: a population‐based study
por: Xiao, Weikai, et al.
Publicado: (2018)

The biogenesis, function and clinical significance of circular RNAs in breast cancer
por: Zeng, Yan, et al.
Publicado: (2022)

Vimentin and p53 expression on epidermal growth factor receptor-positive, oestrogen receptor-negative breast carcinomas.
por: Cattoretti, G., et al.
Publicado: (1988)

Therapeutic Strategies for the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Positive (HR+/HER2+) Breast Cancer: A Review of the Current Literature
por: Thanopoulou, Eirini, et al.
Publicado: (2020)

Efficacy and predictive factors of immune checkpoint inhibitors in metastatic breast cancer: a systematic review and meta-analysis
por: Zou, Yutian, et al.
Publicado: (2020)

Breast‐conserving therapy shows better prognosis in mucinous breast carcinoma compared with mastectomy: A SEER population‐based study
por: Yu, Ping, et al.
Publicado: (2020)

Human epidermal growth factor receptor 2-positive metastatic breast cancer with novel epidermal growth factor receptor -ZNF880 fusion and epidermal growth factor receptor E114K mutations effectively treated with pyrotinib: A case report
por: Yue, Li, et al.
Publicado: (2020)

Heterogeneous PD-L1 expression in metastases impacts immunotherapy response
por: Hu, Xiaoqian, et al.
Publicado: (2023)

AURKAIP1 actuates tumor progression through stabilizing DDX5 in triple negative breast cancer
por: Tian, Wenwen, et al.
Publicado: (2023)

Advances in artificial intelligence to predict cancer immunotherapy efficacy
por: Xie, Jindong, et al.
Publicado: (2023)

Recent advances in the treatment of hormone receptor-positive/human epidermal growth factor 2-positive advanced breast cancer
por: Lv, Huimin, et al.
Publicado: (2021)

Multi-omics analyses unravel DNA damage repair-related clusters in breast cancer with experimental validation
por: Liu, Peng, et al.
Publicado: (2023)

Pertuzumab in human epidermal growth-factor receptor 2-positive breast cancer: clinical and economic considerations
por: Lamond, Nathan WD, et al.
Publicado: (2014)

Pertuzumab for the treatment of patients with human epidermal growth factor receptor 2-positive breast cancer in Japan
por: OSAKO, TOMOFUMI, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_tdabtcjngb00nc8hgc4071ar4j